Aortic Valve

SAN FRANCISCO — Compared with patients assigned surgery, those assigned transcatheter aortic valve replacement had a better Kansas City Cardiomyopathy Questionnaire-Overall Summary, or KCCQ-OS, score at 1 month, 6 months and 12 months, according to new data from the PARTNER 3 trial presented at TCT 2019.

Study findings indicate that an increased scrutiny of surgical outcomes has contributed to an approximately 30% decline in valve surgeries for infective endocarditis, regardless of patients’ injection drug use status — an “unintended consequence” of implementing public reporting of outcomes for aortic valve surgery, researchers said.

SAN FRANCISCO — In the Portico IDE study, 30-day safety and 1-year effectiveness of the Portico transcatheter aortic valve replacement system was noninferior to contemporary commercially available valves in the U.S. for treatment of patients with severe aortic stenosis at high or extreme risk for surgery.

SAN FRANCISCO — In a CT substudy of the PARTNER 3 trial of low surgical risk patients who underwent transcatheter or surgical aortic valve replacement, hypoattenuated leaflet thrombosis and reduced leaflet motion were not associated with death, MI and stroke, according to data presented at TCT 2019.

SAN FRANCISCO — The Transcatheter Cardiovascular Therapeutics Scientific Symposium, to be held here from Wednesday to Sunday, will feature a vast array of scientific data related to interventional cardiology, the meeting’s course directors said during a press conference.

Healio compiled a list of the most-read cardiac and vascular intervention articles in August. This month, our readers were interested in the FDA approval of transcatheter aortic valve replacement devices for use in patients at low surgical risk, FDA recommendations on the signal of late mortality risk associated with paclitaxel-coated devices, the benefits of antiplatelet therapy in patients with atrial fibrillation who had TAVR and much more.

PARIS — Patients with aortic stenosis have poor survival rates if their condition is left untreated, regardless of whether their stenosis is moderate or severe, researchers reported at the European Society of Cardiology Congress.

Early anticoagulation after bioprosthetic aortic valve replacement was associated with short-term reduced risk for stroke in patients who had surgical AVR but not in those who had transcatheter AVR, researchers reported.

In patients with prior atrial fibrillation undergoing transcatheter aortic valve replacement, 6 months of uninterrupted antiplatelet therapy, with or without concomitant oral anticoagulation, was associated with a reduced risk of stroke at 2 years, whereas oral anticoagulation alone did not reduce risk in this population.

Edwards Lifesciences and Medtronic announced that their transcatheter aortic valve replacement systems have been approved by the FDA for use in patients with severe symptomatic aortic stenosis at low surgical risk.